What if you could kill cancer cells by inhibiting the enzyme that enables their uncontrolled division?
Scientific research has shown that telomerase activity is increased in malignant stem and progenitor cells in the bone marrow. Inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells.
Geron is exploring the broad potential of telomerase inhibition across multiple hematologic malignancies.
Our pipeline
We are exploring the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies.
*TELOMERE is expected to begin after an appropriate dose of single agent imetelstat in AML has been identified in the IMpress study.
Ongoing clinical trials:
Patients
We are on a mission to extend and enhance patients’ lives
Discover more about our commitment to patients